Evidence map›Paper›PMID 42561117›Full record

SynthesisJournal of comparative effectiveness research2026

Methodological pitfalls in indirect treatment comparisons: insights from a recent systematic review and analysis for C3 glomerulopathy.

Brian Hutton, James Fotheringham, Andrew Ervin, Raisa Sidhu, Corey Lourenco, Imtiaz A Samjoo, Chris Cameron, Bridget Dunne

Abstract readSystematic Review
In one paragraph

Synthesis in Journal of comparative effectiveness research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Brian HuttonOttawa Hospital Research Institute, Methods & Implementation Research Program, Ottawa, Ontario K1H 8L6, Canada.ORCID 0000-0001-5662-8647
James FotheringhamFaculty of Population Health, School of Medicine & Population Health, University of Sheffield, Sheffield, UK.ORCID 0000-0002-8980-2223
Andrew ErvinNovartis Pharmaceuticals UK Limited, London, UK.ORCID 0009-0004-0809-7035
Raisa SidhuNovartis Pharma AG, Basel, Switzerland.ORCID 0009-0006-0993-9681
Corey LourencoCRG-EVERSANA Canada Inc., Burlington, Ontario L7N 3H8, Canada.ORCID 0000-0001-9075-7661
Imtiaz A SamjooCRG-EVERSANA Canada Inc., Burlington, Ontario L7N 3H8, Canada.ORCID 0000-0003-1415-8055
Chris CameronCRG-EVERSANA Canada Inc., Burlington, Ontario L7N 3H8, Canada.ORCID 0000-0003-3613-760X
Bridget DunneNovartis Ireland Ltd., Ireland.ORCID 0009-0009-6817-3745

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Complement C3Complement Inactivating AgentsKidney DiseasesRare DiseasesClinical Trials, Phase III as TopicComparative Effectiveness ResearchHumansPeptides, CyclicRandomized Controlled Trials as TopicComplement C3Complement Inactivating AgentspegcetacoplanPeptides, CyclicAPPEAR-C3GC3 glomerulopathyfeasibility assessmentindirect treatment comparisoniptacopanmatching-adjusted indirect comparisonpegcetacoplanVALIANT

Identifiers

PMID42561117
PMCPMC13556872

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.